Quarterly report [Sections 13 or 15(d)]

REVENUES - Disaggregated (Details)

v3.25.3
REVENUES - Disaggregated (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Disaggregation of Revenue [Line Items]        
Total revenues $ 69,462 $ 55,307 $ 224,480 $ 121,682
Gross product sales        
Disaggregation of Revenue [Line Items]        
Total revenues 85,624 56,322 225,508 143,728
Discounts and allowances        
Disaggregation of Revenue [Line Items]        
Total revenues (21,557) (17,395) (58,943) (45,348)
Product sales, net        
Disaggregation of Revenue [Line Items]        
Total revenues 64,067 38,927 166,565 98,380
License        
Disaggregation of Revenue [Line Items]        
Total revenues   10,000   10,000
Release of cost share liability        
Disaggregation of Revenue [Line Items]        
Total revenues     39,981  
Milestone        
Disaggregation of Revenue [Line Items]        
Total revenues     3,000  
Delivery of drug supplies, royalty and others        
Disaggregation of Revenue [Line Items]        
Total revenues 5,395 6,380 14,934 13,302
Contract revenues from collaborations        
Disaggregation of Revenue [Line Items]        
Total revenues $ 5,395 $ 16,380 $ 57,915 $ 23,302